Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanoma
Klaudia Borbényi-Galambos(University of Debrecen), Péter Nagy(Semmelweis University), Mihály Cserepes(National Institute of Oncology), Ágnes Czikora(National Institute of Oncology), Réka Szatmári(University of Debrecen), Tamás Ditrói(National Institute of Oncology), Eszter Petra Jurányi(Semmelweis University), Edward E. Schmidt(Montana State University), Erika Tóth(National Institute of Oncology), József Tóvári(HUN-REN Institute of Experimental Medicine), Dorottya Garai(University of Debrecen), Noémi Szántó(National Institute of Oncology), Katalin Erdélyi(National Institute of Oncology), Gabriella Liszkay(National Institute of Oncology)
Cited by 19
Related Papers
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2018|586
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Control of protein function through oxidation and reduction of persulfidated states
|Science Advances|2020|205